Market Exclusive

Analyst Upgrades – Dipexium Pharmaceuticals (NASDAQ:PLXP) Stock Gets Upgraded By Redburn Partners from Outperform to

Analyst Ratings For Dipexium Pharmaceuticals (NASDAQ:PLXP)

Today, Dipexium Pharmaceuticals (NASDAQ:PLXP) stock received an upgrade by Redburn Partners from Outperform.

There are 1 hold rating, 2 buy ratings on the stock.

The current consensus rating on Dipexium Pharmaceuticals (NASDAQ:PLXP) is Buy (Score: 2.67) with a consensus target price of per share, a potential .

Some recent analyst ratings include

Recent Insider Trading Activity For Dipexium Pharmaceuticals (NASDAQ:PLXP)
Dipexium Pharmaceuticals (NASDAQ:PLXP) has insider ownership of 47.70% and institutional ownership of 38.86%.

Recent Trading Activity for Dipexium Pharmaceuticals (NASDAQ:PLXP)
Shares of Dipexium Pharmaceuticals closed the previous trading session at 6.40 up +0.20 3.23% with 17,562 shares trading hands.

Exit mobile version